3648 results for «704»
3648 results
Coronary artery disease: more imaging, less imagination
18 May 2023 – From EuroPCR 2023
In these slides, explore associations between angiography-based FFR and OCT-detected luminal obstruction, prognostic impact of ischaemia vs. plaque vulnerability, CT's mortality foresight, and much more.
TAVI 1: durability, mismatch and challenging anatomy
18 May 2023 – From EuroPCR 2023
Explore TAVI longevity: Five-year Portico valve outcomes, bioprosthetic dysfunction post-surgery or self-expanding TAVI, prosthesis-patient mismatch impact, and innovative valve-in-valve TAVI insights, and more.
ACS - Abstract session
19 May 2023 – From EuroPCR 2023
Looking for a quick review of the Abstract session on acute coronary syndrome (ACS)? Explore the presentation slides available here and catch up on key elements to consider.
TAVI 2: new devices, procedural refinements
19 May 2023 – From EuroPCR 2023
Seeking a recap of the TAVI Abstract session? Dive into the provided slides containing the main points of the presentation.
COVID-19: safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2 (AstraZeneca/Oxford)
02 Jan 2021
Examination of the study methodology and results according to the PICOT principle, SWOT analysis and real-world applicability
20 years of TAVI - Revolutionising medicine since 2002
18 May 2022
Twenty years ago, surgical aortic valve replacement (SAVR) was the only real option for patients with symptomatic aortic stenosis, and if the patient was considered at high operative risk, alternatives were very limited.
Author
Author
Author
Author
The PRE18FFIR trial: Coronary Plaque Activity to Predict Recurrent Events
01 Sep 2022
Alex Sticchi provides his take on the PRE18FFIR trial: Prediction of recurrent events with 18F-Sodium Fluoride to identify ruptured and high-risk coronary artery plaques in patients with myocardial infarction.
Author
COVID-19 vaccines: Burning questions from the community and real-world applicability
13 Jan 2021
View a number of questions of interest to the interventional cardiovascular community, as well as the real-world applicability of COVID-19 vaccine trials.
